1/5/2021

Calcium Chloride Injection

Reason for the Shortage

- American Regent had calcium chloride on shortage due to requirements for complying with good manufacturing practices.
- Amphastar has calcium chloride available.
- Medefil launched calcium chloride 10 mL syringes in early-November 2019.
- Mylan Institutional has withdrawn calcium chloride syringes from the market. The company recalled the syringes in April 2015 due to incompatibility of the syringes and some needless adaptors.
- Pfizer had calcium chloride on shortage due to manufacturing delays.

Available Products

- Calcium chloride intravenous injection, American Regent, 100 mg/mL, 10 mL vial, 10 count, NDC 00517-6710-10
- Calcium chloride intravenous injection, Amphastar, 100 mg/mL, 10 mL Luer-Jet syringe, 10 count, NDC 76329-3304-01
- Calcium chloride intravenous injection, Medefil, Inc., 100 mg/mL, 10 mL syringe, 60 count, NDC 64253-0900-36
- Calcium chloride intravenous injection, Pfizer, 100 mg/mL, 10 mL Ansyr syringe, 10 count, NDC 00409-1631-10
- Calcium chloride intravenous injection, Pfizer, 100 mg/mL, 10 mL LifeShield syringe, 10 count, NDC 00409-4928-34

Estimated Resupply Dates

- All presentations are available.

Updated

Updated January 5, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 6, 2010 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.